thalidomide has been researched along with Lupus Nephritis in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Lupus Nephritis: Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We present two cases of patients diagnosed with lupus nephritis (LN) who demonstrated persistent proteinuria while on standard treatments that markedly improved after addition of thalidomide (THD)." | 8.95 | Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis. ( Carter, JD; Patel, AA; Raturi, R, 2017) |
| " We present two cases of patients diagnosed with lupus nephritis (LN) who demonstrated persistent proteinuria while on standard treatments that markedly improved after addition of thalidomide (THD)." | 4.95 | Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis. ( Carter, JD; Patel, AA; Raturi, R, 2017) |
| "In comparison with untreated mice, mice treated with 10 mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10 mg/kg of thalidomide plus PL or MMF plus PL." | 3.78 | Attenuation of nephritis in lupus-prone mice by thalidomide. ( Choi, KH; Kim, BS; Lee, SK; Lee, SW; Park, KH; Park, YB; Yang, J, 2012) |
| "Thalidomide has been reported as efficacious in refractory cutaneous lupus erythematosus (LE)." | 1.33 | Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. ( Cardoso, CR; Coelho, A; de Souza Papi, JA; Salgado, DR; Schmal, TR; Souto, MI; Waddington Cruz, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raturi, R | 1 |
| Patel, AA | 1 |
| Carter, JD | 1 |
| Lee, SW | 1 |
| Park, YB | 1 |
| Yang, J | 1 |
| Park, KH | 1 |
| Lee, SK | 1 |
| Choi, KH | 1 |
| Kim, BS | 1 |
| Coelho, A | 1 |
| Souto, MI | 1 |
| Cardoso, CR | 1 |
| Salgado, DR | 1 |
| Schmal, TR | 1 |
| Waddington Cruz, M | 1 |
| de Souza Papi, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
1 review available for thalidomide and Lupus Nephritis
| Article | Year |
|---|---|
Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis.
Topics: Adolescent; Adult; Dapsone; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosu | 2017 |
2 other studies available for thalidomide and Lupus Nephritis
| Article | Year |
|---|---|
Attenuation of nephritis in lupus-prone mice by thalidomide.
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; DNA; Dose-Response Relationship, Drug; | 2012 |
Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients.
Topics: Adolescent; Adult; Aged; Brazil; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Disc | 2005 |